2318 studies found for:    Mexico
Show Display Options
Rank Status Study
1 Recruiting A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
Conditions: Heart Failure;   Coronary Artery Disease
Interventions: Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
2 Recruiting ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)
Condition: Acute Coronary Syndrome
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: placebo
3 Terminated Phase III Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban;   Drug: Placebo
4 Completed Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010);   Drug: placebo
5 Recruiting A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Conditions: Breast Cancer;   Neoplasm Metastasis
Interventions: Other: Standard supportive care (packed RBC transfusion);   Drug: epoetin alfa + packed RBC transfusion
6 Recruiting The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Condition: Cardiovascular Disease
Interventions: Drug: bococizumab (PF-04950615);   Drug: Placebo
7 Recruiting Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
Conditions: Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions: Drug: Canagliflozin;   Drug: Placebo
8 Recruiting Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities
Condition: Cardiovascular Disease
Interventions: Drug: Febuxostat;   Drug: Allopurinol
9 Completed
Has Results
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
Conditions: Diabetes Mellitus, Type 2;   Acute Coronary Syndrome
Interventions: Drug: Alogliptin;   Drug: Placebo
10 Terminated
Has Results
Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery
Conditions: Thromboembolism;   Arthroplasty, Replacement, Hip
Intervention:
11 Terminated Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
Conditions: Type 2 Diabetes;   Cardiovascular Disease
Interventions: Drug: TAK-875;   Drug: TAK-875 Placebo
12 Recruiting Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma
Condition: Severe IgE-mediated Asthma
Interventions: Drug: Omalizumab;   Drug: Budesonide;   Drug: Formoterol
13 Recruiting Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: Linagliptin
14 Recruiting Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Intervention: Drug: CP-690,550
15 Completed Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults
Condition: Influenza
Intervention: Drug: favipiravir
16 Active, not recruiting A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
Condition: Cardiovascular Disease, Rheumatoid Arthritis
Interventions: Drug: etanercept;   Drug: tocilizumab [RoActemra/Actemra]
17 Recruiting Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Vildagliptin;   Drug: Insulin;   Drug: Placebo
18 Completed An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: erlotinib [Tarceva]
19 Completed A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Aleglitazar;   Drug: Placebo
20 Completed Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge
Conditions: ACS;   Acute Coronary Syndrome;   Myocardial Infarction;   Unstable Angina;   Coronary Artery Disease
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years